Omega Diagnostics Group PLC
Originally founded in Scotland in 1987 as Omega Diagnostics Ltd., by the current CEO, Andrew Shepherd, the company’s global reputation stems from beginnings as a manufacturer of tests for a range of infectious diseases such as Syphilis, Dengue fever, Chagas disease and Malaria. The company’s export success was officially recognised with the Queen’s Award for Export Achievement in 1993, providing a solid foundation for future success.
In 2006, Omega Diagnostics Group PLC was formed with a strategy to acquire additional products through acquisitions and now focuses on selling a wide range of specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market within three segments: Allergy and Autoimmune, Food Intolerance and Infectious Disease.
With its global headquarters based in Scotland, the group has subsidiaries in Littleport (Cambridge, UK), Reinbek (Germany) and Mumbai (India). It has three manufacturing sites in the UK and one in Germany, each site possessing ISO 13485 and ISO 9001 and compliant with directive 98/79/EC, on In Vitro Diagnostic (IVD) Medical Devices.
Its diagnostic kits and systems are found in hospitals, blood banks, clinics and laboratories around the world and produce information used by physicians and practitioners to diagnose disease, make treatment decisions and monitor patients.
The product range was extended following the acquisition of Genesis Diagnostics Ltd and Cambridge Nutritional Sciences Ltd in September 2007 giving our customers access to tests for the fast growing area of food intolerance testing, as well those for autoimmune diseases – including anaemia, connective tissue disease and renal disease.
In 2010, the group acquired the IVD division of allergy and specific immunotherapy specialist Allergopharma Joachim Ganzer KG, giving further access to a range of allergy tests for over 600 allergens.
Today, Omega Diagnostics Group PLC is one of the UK’s leading companies in the fast growing area of immunoassay and has a global presence in over 100 countries worldwide.